AbbVie Hits Dr. Reddy's With IP Suit Over Generic Zemplar

Law360, New York (June 6, 2013, 10:06 PM EDT) -- Pharmaceuticals maker AbbVie Inc. on Wednesday accused Dr. Reddy's Research Laboratories Ltd. of infringing three drug patents by seeking approval for a generic version of the hyperactive-thyroid medication Zemplar, according to a suit filed in Delaware federal court.

AbbVie, which was spun off by Abbott Laboratories in January, received a letter May 20 from India-based Dr. Reddy's saying the company was seeking U.S. Food and Drug Administration approval for a generic, injectable form of the medication, designed to treat patients suffering from a side effect of...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.